

## **演講摘要**

在國際 COVID-19 疫情嚴峻期間，清冠一號為阻斷病毒的入侵做出了許多努力，為減少死亡和副作用做出了巨大貢獻。再次點燃了國人對中草藥的關注。

全球中藥市場 2022 年達 2,165 億美元，預測 2032 年將達 4,208 億美元，期間內複合年增長率為 6.87%。此對台灣生技產業的發展有重要影響。

但中草藥成分複雜，會因產地、氣候、品種的不同而改變。要了解成分和活性物質需投入大量時間和人力，因此從實驗室研發的角度來看是相當困難的。基於這種困境，解決方案是利用先進儀器和資訊整合來制定新的研發策略。因此，本次演講的內容將從中草藥成分研究到當前國際發展趨勢再到未來自動化的可能性進行分享及討論。

## **Abstract**

During the severe international COVID-19 epidemic, Qingguan No. 1 made many efforts to block the invasion of the virus and made great contributions to reducing deaths and side effects. It once again ignited the Chinese people's attention to Chinese herbal medicine.

The global traditional Chinese medicine market will reach US\$216.5 billion in 2022 and is forecast to reach US\$420.8 billion in 2032, with a compound annual growth rate of 6.87% during the period. This has an important impact on the development of Taiwan's biotechnology industry.

However, the ingredients of Chinese herbal medicine are complex and will change depending on the place of origin, climate, and variety. Understanding the ingredients and active substances requires a lot of time and effort, so it is quite difficult from a laboratory development perspective. Based on this dilemma, the solution is to use advanced instrumentation and information integration to develop new R&D strategies. Therefore, the content of this presentation will be shared and discussed from research on Chinese herbal medicine ingredients to current international development trends to the possibility of future automation.